TLRY (20) SNDL (48) CGC (41) USNA (50) ⌘ Pro Terminal →

Orchestra BioMed Holdings Inc. (OBIO) — RQD Stock Rating Cockpit

$5.91 -2.96% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.87

Orchestra BioMed Holdings Inc. (OBIO) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $366.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on OBIO Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is OBIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Orchestra BioMed Holdings Inc. (NASDAQ: OBIO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $5.91 (-2.96% 1D, market cap $366.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, OBIO ranks #633 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does OBIO compare to TLRY and SNDL in the Health Care sector?

▼

Within the Health Care sector (Medicinal Chemicals and Botanical Products), OBIO carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, TLRY (Tilray Brands Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -3.9%, cap $390.2M) and SNDL (SNDL Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $316.3M). Among the 5-stock peer group, USNA leads on earnings multiple (24.6x) while USNA leads on capital efficiency (7.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for OBIO?

▼

Per OBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001814114), Orchestra BioMed Holdings Inc. generated $33.5M in revenue (+1169.2% YoY), -$52.7M in net income, and -$49.5M in free cash flow against $114.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.87 (-0.72%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-10% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OBIO)Realized 20D OHLCV Swing Band: ±11.7%

Deterministic 5-Pillar Attribution (36/100 Composite)

🔍 WHY OBIO SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (39% of score)

20D Institutional Volume Accumulation (±11.7% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (22% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$5.91-4.4% Next Q

Q2 (-2Q)

Grade E$5.65-1.8% Next Q

Q3 (-1Q)

Grade E$5.55+6.5% Next Q

Current

Grade D-$5.91-8.3% Hist 90D α

Trajectory: E (28) → D- (36)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a OBIO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While OBIO currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.72) and Max Pain ($6.21) forces dealer call-delta covering toward $6.83.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $OBIO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “OBIO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 36%NO 64%Trade / Inspect Odds →

RSI-14 MOMENTUMBULLISH MOMENTUM

57.330 Oversold · 70 Hot

ALTMAN-Z SHIELDDISTRESS RISK (<1.8)

0.20>3.0 Fortress Safe

PIOTROSKI F-SCORESOLID CORE (5–6)

5 / 99-Pt Accounting

52-WEEK LASER RANGE81% OF RANGE

L: $3$5.91H: $7

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 3 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 17 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 16 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on OBIO

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (15)

-35.0% ROIC with 96.0% gross margin and -13.51% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (40)

Altman-Z 0.20 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (42)

17/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like OBIO

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OBIO)

✓Walkthrough of OBIO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

OBIO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +47.01%📐 HORIZONTAL RANGE

2026-11-02O $5.99H $6.09L $5.91C $5.91VOL 274.6K

RES: $7.26SUP: $3.34SMA50: $5.72SMA200: $4.54

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OBIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 OBIO Butterfly Map → + Track OBIO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on OBIO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OBIO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for OBIO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OBIO)

Health Care Rank #633 of 1016 ⚔️ TLRY vs OBIO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OBIO vs. TLRY, SNDL, CGC, USNA)

Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Orchestra BioMed Holdings Inc. (OBIO) ranks #633 by composite RQD confidence (36/100, grade D-) and #495 by equity capitalization ($366.0M). Within this direct 5-issuer industry benchmark cohort, USNA leads on earnings valuation at 24.6x trailing P/E, while USNA leads on capital efficiency and profitability with 7.9% ROIC and 78.3% gross margin. USNA currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with OBIO at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
OBIO ACTIVE Orchestra BioMed Holdings Inc.	D-	36/100	—	96.0%	-35.0%	-2.96%	$366.0M	Benchmark Subject
TLRY Tilray Brands Inc.	E	20/100	—	28.4%	-3.9%	-4.17%	$390.2M	/tlry-vs-obio →
SNDL SNDL Inc.	D	48/100	—	—	—	-4.61%	$316.3M	/sndl-vs-obio →
CGC Canopy Growth Corporation	D-	41/100	—	—	—	-3.33%	$285.6M	/cgc-vs-obio →
USNA USANA Health Sciences Inc.	D	50/100	24.6x	78.3%	7.9%	-0.21%	$265.0M	/usna-vs-obio →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001814114

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Orchestra BioMed Holdings Inc. (OBIO) reported GAAP revenue of $33.5M (+1169.2% vs. FY2024 revenue of $2.6M , and +1113.1% cumulative change since FY2023) , GAAP net income of -$52.7M, operating cash flow of -$49.0M, and free cash flow of -$49.5M (+2.7% YoY). On the balance sheet, OBIO closed FY2025 with $114.9M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$33.5M	-$52.7M	-$49.0M	-$49.5M	$114.9M	—
FY2024 (FY)	2024-12-31	$2.6M	-$61.0M	-$50.6M	-$50.8M	$76.2M	—
FY2023 (FY)	2023-12-31	$2.8M	-$49.1M	-$46.1M	-$46.1M	—	—

3. OBIO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OBIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does OBIO compare to TLRY and SNDL in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for OBIO?

Where is OBIO trading relative to its 50-day, 200-day, and 52-week technical levels?

OBIO last traded at $5.91 (-2.96% on volume of 232,440 shares), positioning the stock +3.32% above its 50-day simple moving average ($5.72) and +30.18% above its 200-day simple moving average ($4.54). Across its 52-week range of $3.46 to $6.50, OBIO sits at the 80.6% percentile with a 14-day RSI of 57.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.7% ($5.22 to $6.60).

OBIO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell OBIO stock right now?

Orchestra BioMed Holdings Inc. (OBIO) currently earns a Roarable Rating of D- (Sell — SELL) with 36/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is OBIO's 12-month price target and RQD AI Jury consensus?

OBIO's 12-month base price target is $5.32 (range $4.15 to $6.83), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: OBIO RQD Cockpit OBIO 12M Forecast OBIO Earnings & Move OBIO Dividends & DRIP OBIO Insiders & 13F OBIO Whale Options OBIO Profit Sankey OBIO News & Why

ROARABLE RATING BRIEF • RQD 36/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

OBIO — Orchestra BioMed Holdings Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:37:42Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, OBIO carries an RQD Score of 36 out of 100, graded D-, with a verdict label of "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are scored as follows:

Fundamental Cash Engine: 3 / 20. The source cites ROIC of -35% and an FCF yield of -13.51%. This is the weakest pillar and indicates the business is not currently generating returns on invested capital or free cash flow to shareholders.
Whale 13F Flow: 14 / 20. Scored on institutional accumulation and options positioning. This is the strongest pillar, suggesting some institutional interest, though the source does not provide holder-level detail to confirm its composition.
Insider Conviction: 3 / 20. Scored on SEC Form 4 and Congressional PTR cluster flow. The low score signals limited insider signaling in support of the stock.
Macro Regime Fit: 8 / 20. The source lists beta of 1.0 and notes sector sensitivity. This pillar reflects market-relative risk rather than a directional call.
Forensic Balance Sheet: 8 / 20. The source cites an Altman Z-Score of 0.2, a Piotroski F-Score of 5/9, and Debt/Equity of 0.5. The Altman reading is the most alarming figure in the dataset and is consistent with elevated financial distress risk, though the Piotroski score is mid-range.

For a prospective investor evaluating the stock today, the upside case rests on the institutional flow pillar and the 96% gross margin reported in the market data; the source does not show that margin converting into operating profit. The valuation tradeoff is stark: the company reports an operating margin of -60% and a net margin of -60%, so conventional earnings multiples cannot be computed from the source. Ripple risk is concentrated in the balance sheet and cash-flow pillars, since sustained negative FCF would pressure the cash balance over time. This brief is educational and is not personalized financial advice.

Business

Orchestra BioMed Holdings Inc. (OBIO) is a NASDAQ-listed issuer in the Health Care sector, classified under the Medicinal Chemicals and Botanical Products industry, per the company profile. The profile does not describe its products, customers, or revenue model. Per the SEC financials, the company reported revenue of $33.5M for FY 2025, up from $2.6M in FY 2024 and $2.8M in FY 2023. The source data does not explain how this revenue is generated.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$33.5M	$-51.8M	$-52.7M	N/A	$-49.5M	$34.7M	N/A
FY 2024	$2.6M	$-64.3M	$-61.0M	N/A	$-50.8M	$22.3M	N/A
FY 2023	$2.8M	$-51.5M	$-49.1M	N/A	$-46.1M	N/A	N/A

Per the SEC financials, the company has reported operating losses in each period shown. Per the market data, gross margin is 96%, operating margin is -60%, net margin is -60%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 5/9, with Debt/Equity of 0.5. Reported cash rose to $34.7M in FY 2025 from $22.3M in FY 2024, while free cash flow remained negative in every period shown.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts feed, six items were reported. Five are tagged as market wire items and rated YELLOW. One item, a Stock Traders Daily report, is tagged RISK WATCH and rated RED. The feed's summaries are generic and do not contain substantive detail beyond headline content.

Headline items include: a Seeking Alpha report titled "Orchestra BioMed Has A Clearer Trial Timeline But A Demanding Valuation"; a TradingView report noting a Chardan Capital Buy rating with a $20 price target; an Investing.com Canada report on H.C. Wainwright reiterating its rating on trial enrollment; and a Stock Titan report describing a balloon designed to deliver liquid medicine into artery walls, to be presented at a heart meeting. The RISK WATCH item is a Stock Traders Daily piece on risk zones for the stock.

Per the butterfly supply-chain graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data. The only sector-level context provided is the Health Care sector classification and beta of 1.0 per the market data.

Open Questions

What are OBIO's products, customers, and revenue model, and what drove the jump in revenue from $2.6M in FY 2024 to $33.5M in FY 2025?
What is the company's cash runway given negative free cash flow of $-49.5M in FY 2025 against reported cash of $34.7M?
What are the debt balances, since the debt field is N/A across all reported periods despite a stated Debt/Equity of 0.5?
What institutional and insider holdings exist, given that the holders section is empty?
What is the basis for the price targets referenced in the news feed, given that the analyst data section is empty?

OBIO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Orchestra BioMed Holdings Inc. (OBIO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to OBIO Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance Australia • 7h ago

Orchestra BioMed Holdings, Inc. (OBIO) stock price, news, quote and history

Yahoo Finance Australia report covering Orchestra BioMed Holdings Inc. (OBIO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 10h ago

Orchestra BioMed Has A Clearer Trial Timeline But A Demanding Valuation

Seeking Alpha report covering Orchestra BioMed Holdings Inc. (OBIO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 13h ago

Chardan Capital maintains Buy rating on Orchestra BioMed Hldgs, $20 price target

TradingView report covering Orchestra BioMed Holdings Inc. (OBIO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com Canada • 16h ago

H.C. Wainwright reiterates Orchestra BioMed stock rating on trial enrollment By Investing.com

Investing.com Canada report covering Orchestra BioMed Holdings Inc. (OBIO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 19h ago

A balloon is designed to put a large volume of liquid medicine into artery walls. It will be presented at a heart meeting.

Stock Titan report covering Orchestra BioMed Holdings Inc. (OBIO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Stock Traders Daily • 22h ago

Precision Trading with Orchestra Biomed Holdings Inc Com (OBIO) Risk Zones

Stock Traders Daily report covering Orchestra BioMed Holdings Inc. (OBIO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.siam.in/ • 1d ago

Orchestra BioMed (OBIO) Falls 5.05% to $5.45 as Shares Retreat Toward Lower Support - Put Spread Alert

https://www.siam.in/ report covering Orchestra BioMed Holdings Inc. (OBIO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com India • 1d ago

Piper Sandler reiterates Orchestra BioMed stock rating on AVIM trial By Investing.com

Investing.com India report covering Orchestra BioMed Holdings Inc. (OBIO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

OBIO Bull vs. Bear Conversation Board — What's Your Call at $5.91?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON OBIO 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $5.36 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is OBIO (D- • RQD 36/100) a Buy at $6.09?

Welcome to the OBIO (Orchestra BioMed Holdings Inc.) Roar Pit. Current RQD Composite is 36/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Medicinal Chemicals and Botanical Products. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $4.87 (-20.0%)

Spot @ $6.09

Pump the brakes on OBIO — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on OBIO, but look at what you are paying: current EV/EBITDA multiples with 96.0% gross margins. Unless Orchestra BioMed Holdings Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $7.49 (+23.0%)

Spot @ $6.09

OBIO cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on OBIO, the market is fixating on short-term headline noise in Medicinal Chemicals and Botanical Products and ignoring the balance sheet and cash flow trajectory. At $6.09 (52-wk range $3.46 - $6.50), any beat on forward guidance forces shorts and underweight funds to chase.